title: The treatment of reflex sympathetic dystrophy syndrome: current concepts.
abstract: Reflex sympathetic dystrophy syndrome is the currently accepted term for a disorder that has previously appeared in the literature under a confusing array of designations: causalgia, Sudeck's atrophy, algoneurodystrophy, shoulder-hand syndrome, etc. The disorder, which was first described in 1864, is characterized by pain, swelling, limited range of motion with associated signs of vasomotor instability, trophic skin changes and patchy bone demineralization. It appears as an exaggerated response of an extremity to injury: trauma, infection, phlebitis or numerous other lesions. In 35 per cent of the RSDS patients, no precipitating event can be identified. The rational treatment of these patients should be based on a thorough understanding of its pathogenesis. While the optimal management is still controversial, there is a consensus that the best results will be achieved if treatment is started early and adapted to the clinical stage of the disease. The role of physical therapy is still debatable. Sympathetic interruption, corticosteroids, calcitonin, beta-blocking agents and more recently bi-phosphonates have been advocated. Proper management may result in the prevention of crippling sequelae.
authors.affiliation: Rehabilitation Center, University Hospital of Ghent, Belgium.
authors.forename: M
authors.initials: M
authors.lastname: van Laere
authors.forename: M
authors.initials: M
authors.lastname: Claessens
mesh_terms: D000700:Analgesics / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001340:Autonomic Nerve Block; D006801:Humans; D026741:Physical Therapy Modalities; D012019:Reflex Sympathetic Dystrophy / Q000503:physiopathology / Q000628:therapy*; D014947:Wounds and Injuries / Q000503:physiopathology*
chemical_list: D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal